Europe Pharmacogenetic Testing in Psychiatry Depression Market - Industry Trends and Forecast to 2028

Europe pharmacogenetic testing in psychiatry/depression market is projected to register a CAGR of 8.9% in the forecast period of 2021 to 2028. The new market report contains data for the historic year 2019, the base year of calculation is 2020 and the forecast period is 2021 to 2028

Market Segmentation:

Europe Pharmacogenetic Testing in Psychiatry/Depression Market, By Type (Whole Genome Sequencing and Array-Based Tests), Genes (CYP2C19, CYP2C9 and VKORC1, CYP2D6, HLA-B, HTR2A/C, HLA-A, CYP3A4, SLC6A4, MTHFR, COMT and Others), Drug Type (Prescription Drugs, Over-the-Counter Medications, Recreational Drugs and Vitamins/Nutraceuticals), Sample Type (Saliva and Blood), Application (Drug Development and Clinical Practice), End User (Pharmaceutical & Biotechnology Companies, Research Centers and Academic Institutes, Healthcare Providers and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Direct-to-Consumer Services and Mail-Order Pharmacies), Country (Germany, U.K., France, Italy, Spain, Switzerland, Netherlands, Russia, Turkey and Rest of Europe) Industry Trends and Forecast to 2028

Some of the major factors contributing to the growth of the Europe pharmacogenetic testing in psychiatry/depression market are:

• Rising demand for precision medicine
• Advanced methodologies present in the fields

Market Players:

The key market players for Europe pharmacogenetic testing in psychiatry/depression market are listed below:

• Myriad Genetics, Inc.
• AltheaDx
• STADA Arzneimittel AG
• Sonic Healthcare
• Thermo Fisher Scientific Inc.
• Coriell Life Sciences
• AB-Biotics, S.A.
• F. Hoffmann-La Roche Ltd
• Luminex Corporation
• Illumina, Inc.
• PerkinElmer Inc.
• myDNA Life Australia Pty Ltd.
• R-Biopharm AG

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 OBJECTIVES OF THE STUDY
• 1.2 MARKET DEFINITION
• 1.3 OVERVIEW OF EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET
• 1.4 LIMITATIONS
• 1.5 MARKETS COVERED

2 MARKET SEGMENTATION

• 2.1 MARKETS COVERED
• 2.2 GEOGRAPHICAL SCOPE
• 2.3 YEARS CONSIDERED FOR THE STUDY
• 2.4 CURRENCY AND PRICING
• 2.5 DBMR TRIPOD DATA VALIDATION MODEL
• 2.6 MULTIVARIATE MODELLING
• 2.7 TYPE LIFELINE CURVE
• 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
• 2.9 DBMR MARKET POSITION GRID
• 2.10 MARKET APPLICATION COVERAGE GRID
• 2.11 VENDOR SHARE ANALYSIS
• 2.12 SECONDARY SOURCES
• 2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 REGULATIONS: EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET

• 5.1 UNITED STATES
  • 5.1.1 ROLE OF FDA
  • 5.1.2 ROLE OF CDC AND HCFA
• 5.2 EUROPEAN UNION
• 5.3 FRANCE
• 5.4 AUSTRALIA
• 5.5 SOUTH KOREA

6 MARKET OVERVIEW

• 6.1 DRIVERS
  • 6.1.1 RISING NUMBER OF POPULATION SUFFERING FROM DEPRESSIVE DISORDER
  • 6.1.2 INITIATIVES TAKEN BY MANUFACTURERS
  • 6.1.3 GROWING BIOTECHNOLOGY SECTOR ALONG WITH RISING HEALTHCARE EXPENDITURE
  • 6.1.4 INCREASING INTEREST FOR PERSONALIZED AND PRECISION MEDICATION
  • 6.1.5 GROWING MEDICAL TOURISM
• 6.2 RESTRAINTS
  • 6.2.1 LACK OF STRONG CLINICAL EVIDENCE
  • 6.2.2 HIGH COST
  • 6.2.3 LACK OF REIMBURSEMENT
• 6.3 OPPORTUNITIES
  • 6.3.1 TECHNOLOGICAL ADVANCEMENTS
  • 6.3.2 EMERGENCE OF NEW PLAYERS
  • 6.3.3 UNTAPPED MARKET
• 6.4 CHALLENGES
  • 6.4.1 STRINGENT GOVERNMENT REGULATION
  • 6.4.2 SHORTAGE OF SKILLED PERSONNEL

7 COVID-19 IMPACT ON EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET

• 7.1 IMPACT ON PRICE
• 7.2 IMPACT ON DEMAND
• 7.3 IMPACT ON SUPPLY
• 7.4 KEY INITIATIVES BY MARKET PLAYER DURING COVID 19

7.5 CONCLUSION:

8 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE

• 8.1 OVERVIEW
• 8.2 WHOLE GENOME SEQUENCING
• 8.3 ARRAY-BASED TESTS

9 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES

• 9.1 OVERVIEW
• 9.2 CYP2C19
• 9.3 CYP2C9 AND VKORC1
• 9.4 CYP2D6
• 9.5 HLA-B
• 9.6 HTR2A/C
• 9.7 HLA-A
• 9.8 CYP3A4
• 9.9 SLC6A4
• 9.10 MTHFR
• 9.11 COMT
• 9.12 OTHERS

10 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE

• 10.1 OVERVIEW
• 10.2 PRESCRIPTION DRUGS
• 10.3 OVER-THE-COUNTER MEDICATIONS
• 10.4 RECREATIONAL DRUGS
• 10.5 VITAMINS/NUTRACEUTICALS

11 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE TYPE

• 11.1 OVERVIEW
• 11.2 SALIVA
• 11.3 BLOOD

12 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION

• 12.1 OVERVIEW
• 12.2 DRUG DEVELOPMENT
• 12.3 CLINICAL PRACTICE

13 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER

• 13.1 OVERVIEW
• 13.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
• 13.3 HEALTHCARE PROVIDERS
• 13.4 RESEARCH CENTERS AND ACADEMIC INSTITUES
• 13.5 OTHERS

14 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL

• 14.1 OVERVIEW
• 14.2 RETAIL PHARMACIES
• 14.3 HOSPITAL PHARMACIES
• 14.4 MAIL-ORDER PHARMACIES
• 14.5 DIRECT-TO-CUSTOMER SERVICES

15 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GEOGRAPHY

• 15.1 EUROPE
  • 15.1.1 U.K.
  • 15.1.2 GERMANY
  • 15.1.3 FRANCE
  • 15.1.4 ITALY
  • 15.1.5 SPAIN
  • 15.1.6 NETHERLANDS
  • 15.1.7 BELGIUM
  • 15.1.8 RUSSIA
  • 15.1.9 SWITZERLAND
  • 15.1.10 TURKEY
  • 15.1.11 REST OF EUROPE

16 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: COMPANY LANDSCAPE

• 16.1 COMPANY SHARE ANALYSIS: EUROPE

17 SWOT ANALYSIS

18 COMPANY PROFILE

• 18.1 MYRIAD GENETICS, INC.
  • 18.1.1 COMPANY SNAPSHOT
  • 18.1.2 REVENUE ANALYSIS
  • 18.1.3 COMPANY SHARE ANALYSIS
  • 18.1.4 PRODUCT PORTFOLIO
  • 18.1.5 RECENT DEVELOPMENTS
• 18.2 THERMO FISHER SCIENTIFIC INC.
  • 18.2.1 COMPANY SNAPSHOT
  • 18.2.2 REVENUE ANALYSIS
  • 18.2.3 COMPANY SHARE ANALYSIS
  • 18.2.4 PRODUCT PORTFOLIO
  • 18.2.5 RECENT DEVELOPMENT
• 18.3 STADA ARZNEIMITTEL AG
  • 18.3.1 COMPANY SNAPSHOT
  • 18.3.2 REVENUE ANALYSIS
  • 18.3.3 COMPANY SHARE ANALYSIS
  • 18.3.4 PRODUCT PORTFOLIO
  • 18.3.5 RECENT DEVELOPMENTS
• 18.4 SONIC HEALTHCARE
  • 18.4.1 COMPANY SNAPSHOT
  • 18.4.2 REVENUE ANALYSIS
  • 18.4.3 COMPANY SHARE ANALYSIS
  • 18.4.4 PRODUCT PORTFOLIO
  • 18.4.5 RECENT DEVELOPMENT
• 18.5 ILLUMINA, INC.
  • 18.5.1 COMPANY SNAPSHOT
  • 18.5.2 REVENUE ANALYSIS
  • 18.5.3 COMPANY SHARE ANALYSIS
  • 18.5.4 PRODUCT PORTFOLIO
  • 18.5.5 RECENT DEVELOPMENTS
• 18.6 AB-BIOTICS, S.A.
  • 18.6.1 COMPANY SNAPSHOT
  • 18.6.2 REVENUE ANALYSIS
  • 18.6.3 6.3 PRODUCT PORTFOLIO
  • 18.6.4 RECENT DEVELOPMENTS
• 18.7 ALTHEADX
  • 18.7.1 COMPANY SNAPSHOT
  • 18.7.2 PRODUCT PORTFOLIO
  • 18.7.3 RECENT DEVELOPMENT
• 18.8 BIOGENIQ INC.
  • 18.8.1 COMPANY SNAPSHOT
  • 18.8.2 PRODUCT PORTFOLIO
  • 18.8.3 RECENT DEVELOPMENT
• 18.9 COLOR
  • 18.9.1 COMPANY SNAPSHOT
  • 18.9.2 PRODUCT PORTFOLIO
  • 18.9.3 RECENT DEVELOPMENTS
• 18.10 CNSDOSE
  • 18.10.1 COMPANY SNAPSHOT
  • 18.10.2 PRODUCT PORTFOLIO
  • 18.10.3 RECENT DEVELOPMENT
• 18.11 CORIELL LIFE SCIENCES
  • 18.11.1 COMPANY SNAPSHOT
  • 18.11.2 PRODUCT PORTFOLIO
  • 18.11.3 RECENT DEVELOPMENTS
• 18.12 DYNAMIC DNA LABORATORIES
  • 18.12.1 COMPANY SNAPSHOT
  • 18.12.2 PRODUCT PORTFOLIO
  • 18.12.3 RECENT DEVELOPMENTS
• 18.13 GENELEX
  • 18.13.1 COMPANY SNAPSHOT
  • 18.13.2 PRODUCT PORTFOLIO
  • 18.13.3 RECENT DEVELOPMENT
• 18.14 GENOMIND, INC.
  • 18.14.1 COMPANY SNAPSHOT
  • 18.14.2 PRODUCT PORTFOLIO
  • 18.14.3 RECENT DEVELOPMENTS
• 18.15 GENXYS
  • 18.15.1 COMPANY SNAPSHOT
  • 18.15.2 PRODUCT PORTFOLIO
  • 18.15.3 RECENT DEVELOPMENTS
• 18.16 HEALTHSPEK
  • 18.16.1 COMPANY SNAPSHOT
  • 18.16.2 PRODUCT PORTFOLIO
  • 18.16.3 RECENT DEVELOPMENT
• 18.17 HUDSONALPHA HEALTH ALLIANCE (A DIVISION OF HUDSONALPHA)
  • 18.17.1 COMPANY SNAPSHOT
  • 18.17.2 PRODUCT PORTFOLIO
  • 18.17.3 RECENT DEVELOPMENT
• 18.18 LUMINEX CORPORATION
  • 18.18.1 COMPANY SNAPSHOT
  • 18.18.2 REVENUE ANALYSIS
  • 18.18.3 PRODUCT PORTFOLIO
  • 18.18.4 RECENT DEVELOPMENTS
• 18.19 MILLENNIUM HEALTH
  • 18.19.1 COMPANY SNAPSHOT
  • 18.19.2 PRODUCT PORTFOLIO
  • 18.19.3 RECENT DEVELOPMENTS
• 18.20 MYDNA LIFE AUSTRALIA PTY LTD.
  • 18.20.1 COMPANY SNAPSHOT
  • 18.20.2 PRODUCT PORTFOLIO
  • 18.20.3 RECENT DEVELOPMENT
• 18.21 ONEOME
  • 18.21.1 COMPANY SNAPSHOT
  • 18.21.2 PRODUCT PORTFOLIO
  • 18.21.3 RECENT DEVELOPMENTS
• 18.22 OMECARE
  • 18.22.1 COMPANY SNAPSHOT
  • 18.22.2 PRODUCT PORTFOLIO
  • 18.22.3 RECENT DEVELOPMENT
• 18.23 PERKINELMER INC.
  • 18.23.1 COMPANY SNAPSHOT
  • 18.23.2 REVENUE ANALYSIS
  • 18.23.3 PRODUCT PORTFOLIO
  • 18.23.4 RECENT DEVELOPMENTS
• 18.24 R-BIOPHARM AG
  • 18.24.1 COMPANY SNAPSHOT
  • 18.24.2 PRODUCT PORTFOLIO
  • 18.24.3 RECENT DEVELOPMENTS

19 QUESTIONNAIRE

20 RELATED REPORTS

LIST OF TABLES

• TABLE 1 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, (2021-2028)(USD MILLION)
• TABLE 2 EUROPE WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
• TABLE 3 EUROPE ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
• TABLE 4 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, (2021-2028)(USD MILLION)
• TABLE 5 EUROPE CYP2C19 IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
• TABLE 6 EUROPE CYP2C9 AND VKORC1 IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
• TABLE 7 EUROPE CYP2D6 IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
• TABLE 8 EUROPE HLA-B IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
• TABLE 9 EUROPE HTR2A/C IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
• TABLE 10 EUROPE HLA-A IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
• TABLE 11 EUROPE CYP3A4 IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
• TABLE 12 EUROPE SLC6A4 IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
• TABLE 13 EUROPE MTHFR IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
• TABLE 14 EUROPE COMT IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
• TABLE 15 EUROPE OTHERS IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
• TABLE 16 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, (2021-2028)(USD MILLION)
• TABLE 17 EUROPE PRESCRIPTION DRUGS IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
• TABLE 18 EUROPE OVER-THE-COUNTER MEDICATIONS IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
• TABLE 19 EUROPE RECREATIONAL DRUGS IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
• TABLE 20 EUROPE VITAMINS/NUTRACEUTICALS IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
• TABLE 21 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE TYPE, (2021-2028)(USD MILLION)
• TABLE 22 EUROPE SALIVA IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
• TABLE 23 EUROPE BLOOD IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
• TABLE 24 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, (2021-2028)(USD MILLION)
• TABLE 25 EUROPE DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
• TABLE 26 EUROPE CLINICAL PRACTICE IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
• TABLE 27 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, (2021-2028)(USD MILLION)
• TABLE 28 EUROPE PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
• TABLE 29 EUROPE HEALTHCARE PROVIDERS IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
• TABLE 30 EUROPE RESEARCH CENTRES AND ACADEMIC INSTITUTES IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
• TABLE 31 EUROPE OTHERS IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
• TABLE 32 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, (2021-2028)(USD MILLION)
• TABLE 33 EUROPE RETAIL PHARMACIES IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
• TABLE 34 EUROPE HOSPITAL PHARMACIES IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
• TABLE 35 EUROPE MAIL-ORDER PHARMACIES IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION))
• TABLE 36 EUROPE DIRECT-TO-CUSTOMER SERVICES IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
• TABLE 37 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
• TABLE 38 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
• TABLE 39 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)
• TABLE 40 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
• TABLE 41 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE, 2021-2028 (USD MILLION)
• TABLE 42 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
• TABLE 43 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
• TABLE 44 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
• TABLE 45 U.K. PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
• TABLE 46 U.K. PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)
• TABLE 47 U.K. PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
• TABLE 48 U.K. PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE, 2021-2028 (USD MILLION)
• TABLE 49 U.K. PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
• TABLE 50 U.K. PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
• TABLE 51 U.K. PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
• TABLE 52 GERMANY PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
• TABLE 53 GERMANY PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)
• TABLE 54 GERMANY PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
• TABLE 55 GERMANY PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE, 2021-2028 (USD MILLION)
• TABLE 56 GERMANY PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
• TABLE 57 GERMANY PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
• TABLE 58 GERMANY PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
• TABLE 59 FRANCE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
• TABLE 60 FRANCE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)
• TABLE 61 FRANCE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
• TABLE 62 FRANCE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE, 2021-2028 (USD MILLION)
• TABLE 63 FRANCE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
• TABLE 64 FRANCE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
• TABLE 65 FRANCE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
• TABLE 66 ITALY PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
• TABLE 67 ITALY PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)
• TABLE 68 ITALY PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
• TABLE 69 ITALY PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE, 2021-2028 (USD MILLION)
• TABLE 70 ITALY PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
• TABLE 71 ITALY PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
• TABLE 72 ITALY PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
• TABLE 73 SPAIN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
• TABLE 74 SPAIN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)
• TABLE 75 SPAIN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
• TABLE 76 SPAIN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE, 2021-2028 (USD MILLION)
• TABLE 77 SPAIN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
• TABLE 78 SPAIN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
• TABLE 79 SPAIN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
• TABLE 80 NETHERLANDS PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
• TABLE 81 NETHERLANDS PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)
• TABLE 82 NETHERLANDS PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
• TABLE 83 NETHERLANDS PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE, 2021-2028 (USD MILLION)
• TABLE 84 NETHERLANDS PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
• TABLE 85 NETHERLANDS PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
• TABLE 86 NETHERLANDS PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
• TABLE 87 BELGIUM PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
• TABLE 88 BELGIUM PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)
• TABLE 89 BELGIUM PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
• TABLE 90 BELGIUM PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE, 2021-2028 (USD MILLION)
• TABLE 91 BELGIUM PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
• TABLE 92 BELGIUM PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
• TABLE 93 BELGIUM PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
• TABLE 94 RUSSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
• TABLE 95 RUSSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)
• TABLE 96 RUSSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
• TABLE 97 RUSSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE, 2021-2028 (USD MILLION)
• TABLE 98 RUSSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
• TABLE 99 RUSSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
• TABLE 100 RUSSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
• TABLE 101 SWITZERLAND PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
• TABLE 102 SWITZERLAND PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)
• TABLE 103 SWITZERLAND PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
• TABLE 104 SWITZERLAND PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE, 2021-2028 (USD MILLION)
• TABLE 105 SWITZERLAND PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
• TABLE 106 SWITZERLAND PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
• TABLE 107 SWITZERLAND PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
• TABLE 108 TURKEY PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
• TABLE 109 TURKEY PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)
• TABLE 110 TURKEY PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
• TABLE 111 TURKEY PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE, 2021-2028 (USD MILLION)
• TABLE 112 TURKEY PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
• TABLE 113 TURKEY PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
• TABLE 114 TURKEY PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
• TABLE 115 REST OF EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)

LIST OF FIGURES

• FIGURE 1 EUROPE PHARMACOGENTIC TESTIG IN PSYCHIATRY/DEPRESSION MARKET: SEGMENTATION
• FIGURE 2 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRIC/DEPRESSION MARKET: DATA TRIANGULATION
• FIGURE 3 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRIC/DEPRESSION MARKET: DROC ANALYSIS
• FIGURE 4 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRIC/DEPRESSION MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
• FIGURE 5 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRIC/DEPRESSION MARKET: COMPANY RESEARCH ANALYSIS
• FIGURE 6 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRIC/DEPRESSION MARKET: INTERVIEW DEMOGRAPHICS
• FIGURE 7 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRIC/DEPRESSION MARKET: DBMR MARKET POSITION GRID
• FIGURE 8 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: MARKET APPLICATION COVERAGE GRID
• FIGURE 9 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: VENDOR SHARE ANALYSIS
• FIGURE 10 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: SEGMENTATION
• FIGURE 11 INITIATIVES TAKEN BY MANUFACTURERS IS EXPECTED TO DRIVE THE EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
• FIGURE 12 WHOLE GENOME SEQUENCING SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET IN 2021 & 2028
• FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET
• FIGURE 14 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY TYPE, 2021-2028
• FIGURE 15 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY TYPE, 2021-2028 (USD MILLION)
• FIGURE 16 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY TYPE, CAGR (2021-2028)
• FIGURE 17 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY TYPE, LIFELINE CURVE
• FIGURE 18 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY GENES, 2021-2028
• FIGURE 19 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY GENES, 2021-2028 (USD MILLION)
• FIGURE 20 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY GENES, CAGR (2021-2028)
• FIGURE 21 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY GENES, LIFELINE CURVE
• FIGURE 22 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DRUG TYPE, 2021-2028
• FIGURE 23 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DRUG TYPE, 2021-2028 (USD MILLION)
• FIGURE 24 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DRUG TYPE, CAGR (2021-2028)
• FIGURE 25 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DRUG TYPE, LIFELINE CURVE
• FIGURE 26 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY SAMPLE TYPE, 2021-2028
• FIGURE 27 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY SAMPLE TYPE, 2021-2028 (USD MILLION)
• FIGURE 28 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DRUG TYPE, CAGR (2021-2028)
• FIGURE 29 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY SAMPLE TYPE, LIFELINE CURVE
• FIGURE 30 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY APPLICATION, 2021-2028
• FIGURE 31 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY APPLICATION, 2021-2028 (USD MILLION)
• FIGURE 32 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY APPLICATION, CAGR (2021-2028)
• FIGURE 33 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY APPLICATION, LIFELINE CURVE
• FIGURE 34 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY END USER, 2021-2028
• FIGURE 35 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY END USER, 2021-2028 (USD MILLION)
• FIGURE 36 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY END USER, CAGR (2021-2028)
• FIGURE 37 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY END USER, LIFELINE CURVE
• FIGURE 38 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DISTRIBUTION CHANNEL, 2021-2028
• FIGURE 39 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
• FIGURE 40 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
• FIGURE 41 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
• FIGURE 42 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: SNAPSHOT (2020)
• FIGURE 43 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2020)
• FIGURE 44 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2021 & 2028)
• FIGURE 45 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2020 & 2028)
• FIGURE 46 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY TYPE (2021-2028)
• FIGURE 47 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: COMPANY SHARE 2020 (%)